Skip to content

Exome Analysis in Hearing Impaired Patients

Exome Analysis on Hearing Impaired Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03557879
Acronym
NGS-NSHL
Enrollment
30
Registered
2018-06-15
Start date
2018-06-04
Completion date
2019-06-01
Last updated
2018-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hearing Impairment

Keywords

Hearing impairment, familial

Brief summary

Hearing impairment is the most frequent sensory deficit in humans and affects one newborn out of 500. The prevalence rises to 3,5/1000 in teenagers due to retarded forms. Most of hearing impairments (about two thirds) have a genetic origin, with recessive, dominant or X-linked mode of inheritance. Some rare forms can be linked to mitochondrial DNA. Molecular diagnosis (i.e. defining the molecular basis of the disease, genes and precise DNA variants) is essential for the follow-up of patients and families. The project intends to perform exome sequencing on 30 samples of families presenting with hearing impairment. Families have been included based on the genetic origin of the hearing impairment (familial cases) and the exclusion of the involvement of 74 known deafness genes. Exome sequencing (sequencing of the coding regions of all known genes, about 22,000) in these cases may underly new gene/disease relationships.

Detailed description

Exome sequencing will be performed of 10 trios that each include two affected and one non affected members of a family. Filtering of variants will be performed based on frequency. For each trio, data will be analysed in parallel to follow segregation of the variant(s) in candidate genes. The selected candidate genes will be further characterized in order to ascertain their involvement in hearing function. Finally, once these new genes are well defined as deafness genes , their screening will be added to existing diagnostic panels.

Interventions

DNA extracted from samples will undergo exome sequencing, i.e. sequencing of the coding regions of all known human genes (about 22,000)

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
FAMILY_BASED
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Families presenting with familial hearing impairment, underlying the genetic basis, for whom 74 deafness genes have already been excluded (no evidence of pathogenic genotype)

Exclusion criteria

\- sporadic cases of hearing impairment, or resolved familial cases

Design outcomes

Primary

MeasureTime frameDescription
identification of candidate genes1 dayDescription: a candidate gene would present a genotype (combination of DNA variants) compatible with the transmission mode and several lines of evidence of the pathogenic effect of the DNA variants

Secondary

MeasureTime frameDescription
Quality assessment of the exome sequencing1 dayQuality assessment of the exome sequencing
Quality assessment of the bioinformatics pipelines used1 dayQuality assessment of the bioinformatics pipelines used

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026